Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.
Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser C, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S; Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team.
Ramirez SI, et al. Among authors: sieg sf.
JCI Insight. 2022 Dec 22;7(24):e163471. doi: 10.1172/jci.insight.163471.
JCI Insight. 2022.
PMID: 36378539
Free PMC article.